Progenity Company

Progenity is an innovative biotech company that was founded in 2010 and went public in 2020. The idea is to improve the diagnosis of disease and improve patient outcomes through localized treatment with targeted therapies.
Progenity is developing the Preecludia preeclampsia rule-out test to help physicians evaluate and manage their patients in a whole new way. For the first time in the US, physicians will have a test based on measuring biomarkers of the underlying pathophysiology of preeclampsia.
Technology: Other
Industry: Pregnancy & Nursing
Headquarters: Carlsbad, California, United States
Founded Date: 01-01-2010
Employees Number: 251-500
Funding Status: IPO
Investors Number: 1
Total Funding: $248,500,000
Estimated Revenue: $10M to $50M
Last Funding Date: 2021-10-04
Last Funding Type: Post-IPO Equity

Visit Website
https://twitter.com/progenity
Register and Claim Ownership